Department of Justice Declines to Intervene in Lawsuit against Gilead Sciences Regarding Ranexa®

Document Sample
Department of Justice Declines to Intervene in Lawsuit against Gilead Sciences Regarding Ranexa® Powered By Docstoc
					Department of Justice Declines to Intervene in
Lawsuit against Gilead Sciences Regarding
Ranexa®
December 16, 2010 04:18 PM Eastern Time  

FOSTER CITY, Calif.--(EON: Enhanced Online News)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today
that, after conducting an investigation, the United States Department of Justice (“DOJ”) has notified the United
States District Court for the Northern District of California “of its decision not to intervene” in a False Claims Act
lawsuit filed by a former employee of CV Therapeutics, Inc. regarding the promotion of Ranexa® (ranolazine
extended release tablets). Gilead acquired CV Therapeutics in April 2009.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative
therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North
America, Europe and Australia.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call
Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts
Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Nathan Kaiser, 650-522-1853 (Media)

Permalink: http://eon.businesswire.com/news/eon/20101216006613/en

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:60
posted:12/16/2010
language:English
pages:1
Description: FOSTER CITY, Calif.--(EON: Enhanced Online News)--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that, after conducting an investigation, the United States Department of Justice (“DOJ”) has notified the United States District Court for the Northern District of California “of its decision not to intervene” in a False Claims Act lawsuit filed by a former employee of CV Therapeutics, Inc. regarding the promotion of Ranexa® (ranolazine extended release tablets). Gilead acquired CV Therapeutics a style='font-s
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.